Yekutiel Aya, Shalit Itamar, Shadkchan Yona, Osherov Nir
Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv 69978, Tel-Aviv, Israel.
Antimicrob Agents Chemother. 2004 Sep;48(9):3279-83. doi: 10.1128/AAC.48.9.3279-3283.2004.
Caspofungin (CAS) inhibits fungal cell wall synthesis. Sulfamethoxazole (SMX) inhibits folate biosynthesis and is active in vitro against Aspergillus spp. We studied the activities of the combination of CAS and SMX against 31 Aspergillus isolates and compared them with that of SMX combined with amphotericin B (AMB) or itraconazole (ITC). MICs and minimal effective concentrations (MECs) were determined by the NCCLS broth microdilution method. With MIC endpoints, the combination of SMX and CAS showed synergy or synergy to additivity against 29 of 31 isolates. With MEC endpoints, synergy to additivity was found against 12 of 31 isolates and indifference was displayed against the rest of them. SMX in combination with AMB or ITC was not truly synergistic, while synergy to additivity was found for SMX-AMB and SMX-ITC against 17 of 31 and 3 of 12 isolates, respectively. No antagonism was found with any of the drug combinations. Further analysis of the synergy of CAS and SMX was performed by detailed measurement of hyphal length by microscopy and time-dependent 2,3-bis(2-methoxy-4-nitro-5-[(sulfenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT)-based hyphal damage experiments. With MEC endpoints, the combination of CAS and SMX was characterized by a greater than 50% decrease in hyphal length compared to the hyphal lengths achieved with double the concentration of each drug alone. The XTT-based hyphal damage studies showed a statistically significant (P < 0.05) reduction in viability with CAS and SMX in combination compared to the viabilities achieved with double the concentration of each drug alone. These findings support the synergy results found by using MIC endpoints and suggest that visual MEC measurements may not be sufficient to identify the synergistic interactions seen by more sensitive, quantitative methods. Animal models are required to validate the significance of the synergy of CAS and SMX against Aspergillus spp. observed in vitro.
卡泊芬净(CAS)可抑制真菌细胞壁合成。磺胺甲恶唑(SMX)抑制叶酸生物合成,在体外对曲霉属真菌具有活性。我们研究了CAS与SMX联合用药对31株曲霉菌分离株的活性,并将其与SMX联合两性霉素B(AMB)或伊曲康唑(ITC)的活性进行了比较。采用美国国立临床实验室标准化委员会(NCCLS)肉汤微量稀释法测定最低抑菌浓度(MIC)和最低有效浓度(MEC)。以MIC为终点,SMX与CAS联合用药对31株分离株中的29株显示协同作用或协同至相加作用。以MEC为终点,对31株分离株中的12株显示协同至相加作用,其余分离株则无差异。SMX与AMB或ITC联合用药并非真正具有协同作用,而SMX-AMB和SMX-ITC联合用药分别对31株中的17株和12株中的3株显示协同至相加作用。所有药物组合均未发现拮抗作用。通过显微镜详细测量菌丝长度以及基于2,3-双(2-甲氧基-4-硝基-5-[(亚磺酰氨基)羰基]-2H-四唑氢氧化合物(XTT)的时间依赖性菌丝损伤实验,对CAS与SMX的协同作用进行了进一步分析。以MEC为终点,与单独使用每种药物双倍浓度时所达到的菌丝长度相比,CAS与SMX联合用药时菌丝长度减少超过50%。基于XTT的菌丝损伤研究表明,与单独使用每种药物双倍浓度时所达到的活力相比,CAS与SMX联合用药时活力有统计学意义(P < 0.05)的降低。这些发现支持了使用MIC终点所发现的协同作用结果,并表明肉眼观察MEC测量可能不足以识别更敏感的定量方法所观察到的协同相互作用。需要动物模型来验证体外观察到的CAS与SMX联合用药对曲霉属真菌的协同作用的意义。